专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013006278A2 IDENTITY ELUCIDATION OF UNKNOWN METABOLITES 审中-公开
标题翻译：身份识别未知代谢物
公开(公告)号：WO2013006278A2
公开(公告)日：2013-01-10
申请号：PCT/US2012/043461
申请日：2012-06-21
申请人： METABOLON, INC. , HELMHOLTZ ZENTRUM MUENCHEN , MILBURN, Michael , KASTENMUELLER, Gabriele , KRUMSIEK, Jan , SUHRE, Karsten
发明人： MILBURN, Michael , KASTENMUELLER, Gabriele , KRUMSIEK, Jan , SUHRE, Karsten
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6872 , C12Q1/68 , C12Q1/6883 , C12Q1/6886 , G01N33/6848 , G01N2570/00 , G01N2800/7066
摘要： A method of elucidating the identity of an unknown metabolite comprising measuring amounts of known and unknown metabolites in subjects; associating the unknown metabolite with a specific gene from a gene association study; determining a protein associated with the specific gene and analyzing information for the protein; associating the unknown metabolite with concentrations and/or ratios of other metabolites in subjects; obtaining chemical structural data for the unknown metabolite; and using the information obtained to elucidate the identity of the unknown metabolite.
摘要翻译：阐明未知代谢物的身份的方法，包括测量受试者中已知和未知代谢物的量; 将未知代谢物与基因关联研究中的特定基因缔合; 确定与所述特定基因相关的蛋白质并分析所述蛋白质的信息; 将未知代谢物与受试者中其他代谢物的浓度和/或比例相关联; 获得未知代谢物的化学结构数据; 并使用获得的信息来阐明未知代谢物的身份。

2. 发明申请

WO2013006278A3 IDENTITY ELUCIDATION OF UNKNOWN METABOLITES 审中-公开
标题翻译：未知代谢物的身份验证
公开(公告)号：WO2013006278A3
公开(公告)日：2013-04-04
申请号：PCT/US2012043461
申请日：2012-06-21
申请人： METABOLON INC , HELMHOLTZ ZENTRUM MUENCHEN , MILBURN MICHAEL , KASTENMUELLER GABRIELE , KRUMSIEK JAN , SUHRE KARSTEN
发明人： MILBURN MICHAEL , KASTENMUELLER GABRIELE , KRUMSIEK JAN , SUHRE KARSTEN
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6872 , C12Q1/68 , C12Q1/6883 , C12Q1/6886 , G01N33/6848 , G01N2570/00 , G01N2800/7066
摘要： A method of elucidating the identity of an unknown metabolite comprising measuring amounts of known and unknown metabolites in subjects; associating the unknown metabolite with a specific gene from a gene association study; determining a protein associated with the specific gene and analyzing information for the protein; associating the unknown metabolite with concentrations and/or ratios of other metabolites in subjects; obtaining chemical structural data for the unknown metabolite; and using the information obtained to elucidate the identity of the unknown metabolite.
摘要翻译：一种阐明未知代谢物身份的方法，包括测量受试者中已知和未知代谢物的量; 将未知代谢物与来自基因关联研究的特定基因相关联; 确定与特定基因相关的蛋白质并分析蛋白质的信息; 将未知代谢物与受试者中其他代谢物的浓度和/或比率相关联; 获得未知代谢物的化学结构数据; 并使用获得的信息来阐明未知代谢物的身份。

3. 发明申请

WO2010060996A3 PREDICTION OF LIPID-METABOTYPE-RELATED PHYSIOLOGICAL SUSCEPTIBILITIES 审中-公开
标题翻译：脂肪代谢相关生理学可能性的预测
公开(公告)号：WO2010060996A3
公开(公告)日：2010-08-12
申请号：PCT/EP2009066003
申请日：2009-11-27
申请人： HELMHOLTZ ZENTRUM MUENCHEN , SUHRE KARSTEN , GIEGER CHRISTIAN
发明人： SUHRE KARSTEN , GIEGER CHRISTIAN
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to a method for determining a predisposition of a human subject for physiological susceptibilities that result from alterations in lipid metabolism, wherein the physiological susceptibilities are selected from sensitivity to functional food, physical health schemes, identification of non-responsiveness to treatment by diet or physical activity. The present invention further relates to a method for determining a predisposition of a human subject for physiological susceptibilities that result from alterations in lipid metabolism, wherein the physiological susceptibilities are selected from sensitivity to drug treatment or identification of non- responsiveness to treatment by medication. The methods of the present invention comprise determining, in a sample obtained from the human subject, the genotype of that person with respect to at least two genetic polymorphisms selected from the group consisting of a) rs2014355; b) rs11161510; c) rs2286963; d) rs174548; e) rs9393903; f) rs168622; g) rs541503; h) rs2046813; i) rs272889; j) rs2216405; k) rs7156144; l) rs8396; m) rs7094971; and n) rs603424; wherein the presence of one or two copies of the minor allele of at least two genetic polymorphisms is indicative of a predisposition for said physiological susceptibilities. The polymorphisms listed above are located in the following genes: SCAD, MCAD, LCAD, FADS1, EL0VL2, SPTLC3, PHGDH, ACSL1, OCTN1, CPS1, PLEKHH1, ETFDH, SLC16A9 and SCD.
摘要翻译：本发明涉及一种用于确定人类受试者对由脂质代谢改变引起的生理敏感性的易感性的方法，其中所述生理敏感性选自对功能性食物的敏感性，身体健康方案，对对治疗的无反应性的鉴定饮食或身体活动。本发明还涉及一种用于确定人类受试者对由脂质代谢改变引起的生理敏感性的倾向的方法，其中所述生理敏感性选自药物治疗的敏感性或通过药物治疗的不敏感性。本发明的方法包括在从人受试者获得的样品中确定该人对于至少两种选自以下的遗传多态性的基因型：a）rs2014355; b）rs11161510; c）rs2286963; d）rs174548; e）rs9393903; f）rs168622; g）rs541503; h）rs2046813; i）rs272889; j）rs2216405; k）rs7156144; l）rs8396; m）rs7094971; 和n）rs603424; 其中至少两个遗传多态性的次要等位基因的一个或两个拷贝的存在表示所述生理敏感性的易感性。以上列出的多态性位于以下基因：SCAD，MCAD，LCAD，FADS1，EL0VL2，SPTLC3，PHGDH，ACSL1，OCTN1，CPS1，PLEKHH1，ETFDH，SLC16A9和SCD。

4. 发明申请

WO2010060996A2 PREDICTION OF LIPID-METABOTYPE-RELATED PHYSIOLOGICAL SUSCEPTIBILITIES 审中-公开
标题翻译：脂肪代谢相关生理学可能性的预测
公开(公告)号：WO2010060996A2
公开(公告)日：2010-06-03
申请号：PCT/EP2009/066003
申请日：2009-11-27
申请人： Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) , SUHRE, Karsten , GIEGER, Christian
发明人： SUHRE, Karsten , GIEGER, Christian
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to a method for determining a predisposition of a human subject for physiological susceptibilities that result from alterations in lipid metabolism, wherein the physiological susceptibilities are selected from sensitivity to functional food, physical health schemes, identification of non-responsiveness to treatment by diet or physical activity. The present invention further relates to a method for determining a predisposition of a human subject for physiological susceptibilities that result from alterations in lipid metabolism, wherein the physiological susceptibilities are selected from sensitivity to drug treatment or identification of non-responsiveness to treatment by medication. The methods of the present invention comprise determining, in a sample obtained from the human subject, the genotype of that person with respect to at least two genetic polymorphisms selected from the group consisting of a) rs2014355; wherein the minor allele is represented by a cytidine and the major allele is represented by a thymidine; b) rs11161510; wherein the minor allele is represented by a thymidine and the major allele is represented by a cytidine; c) rs2286963; wherein the minor allele is represented by a guanosine and the major allele is represented by a thymidine; d) rs174548; wherein the minor allele is represented by a guanosine and the major allele is represented by a cytidine; e) rs9393903; wherein the minor allele is represented by a adenosine and the major allele is represented by a guanosine; f) rs168622; wherein the minor allele is represented by a thymidine and the major allele is represented by a guanosine; g) rs541503; wherein the minor allele is represented by a cytidine and the major allele is represented by a thymidine; h) rs2046813; wherein the minor allele is represented by a cytidine and the major allele is represented by a thymidine; i) rs272889; wherein the minor allele is represented by a adenosine and the major allele is represented by a guanosine; j) rs2216405; wherein the minor allele is represented by a guanosine and the major allele is represented by a adenosine; k) rs7156144; wherein the minor allele is represented by a adenosine and the major allele is represented by a guanosine; I) rs8396; wherein the minor allele is represented by a cytidine and the major allele is represented by a thymidine; m) rs7094971; wherein the minor allele is represented by a guanosine and the major allele is represented by a adenosine; n) rs603424; wherein the minor allele is represented by a adenosine and the major allele is represented by a guanosine; and/or o) at least one genetic polymorphism that is in linkage disequilibrium with any of the genetic polymorphisms of (a) to (n), wherein the presence of one or two copies of the minor allele of at least two genetic polymorphisms is indicative of a predisposition for said physiological susceptibilities.
摘要翻译：本发明涉及一种用于确定由于脂质代谢改变而导致的生理敏感性的人类受试者易感性的方法，其中所述生理敏感性选自对功能性食物的敏感性，身体健康方案，对治疗无反应性的鉴定饮食或身体活动。本发明还涉及一种用于确定人类受试者对由脂质代谢改变引起的生理敏感性的易感性的方法，其中所述生理敏感性选自对药物治疗的敏感性或鉴定对药物治疗的不响应性。本发明的方法包括在从人受试者获得的样品中确定该人的基因型，其选自以下组中的至少两种遗传多态性：a）rs2014355; 其中次要等位基因由胞苷代表，主要等位基因由胸苷代表; b）rs11161510; 其中次要等位基因由胸苷代表，主要等位基因由胞苷代表; c）rs2286963; 其中次要等位基因由鸟苷代表，主等位基因由胸苷代表; d）rs174548; 其中次要等位基因由鸟苷代表，主要等位基因由胞苷代表; e）rs9393903; 其中次要等位基因由腺苷表示，主要等位基因由鸟苷代表; f）rs168622; 其中次要等位基因由胸苷代表，主要等位基因由鸟苷代表; g）rs541503; 其中次要等位基因由胞苷代表，主要等位基因由胸苷代表; h）rs2046813; 其中次要等位基因由胞苷代表，主要等位基因由胸苷代表; i）rs272889; 其中次要等位基因由腺苷表示，主要等位基因由鸟苷代表; j）rs2216405; 其中次要等位基因由鸟苷代表，主要等位基因由腺苷表示; k）rs7156144; 其中次要等位基因由腺苷表示，主要等位基因由鸟苷代表; I）rs8396; 其中次要等位基因由胞苷代表，主要等位基因由胸苷代表; m）rs7094971; 其中次要等位基因由鸟苷代表，主要等位基因由腺苷表示; n）rs603424; 其中次要等位基因由腺苷表示，主要等位基因由鸟苷代表; 和/或o）与（a）至（n）的任何遗传多态性处于连锁不平衡的至少一个遗传多态性，其中存在至少两个遗传多态性的次要等位基因的一个或两个拷贝是指示对于所述生理敏感性的倾向。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式